These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

942 related items for PubMed ID: 15344210

  • 21. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA.
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
    [Abstract] [Full Text] [Related]

  • 22. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study.
    Rhee Y, Kang M, Min Y, Byun D, Chung Y, Ahn C, Baek K, Mok J, Kim D, Kim D, Kim H, Kim Y, Myoung S, Kim D, Lim SK.
    Osteoporos Int; 2006 Dec; 17(12):1801-7. PubMed ID: 17019520
    [Abstract] [Full Text] [Related]

  • 23. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B, San Martin J, Crans G, Pavo I.
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [Abstract] [Full Text] [Related]

  • 24. Alendronate for the treatment of osteoporosis in men.
    Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A.
    N Engl J Med; 2000 Aug 31; 343(9):604-10. PubMed ID: 10979796
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Effects of 5-year treatment with elcatonin and alfacalcidol on lumbar bone mineral density and the incidence of vertebral fractures in postmenopausal women with osteoporosis: a retrospective study.
    Iwamoto J, Takeda T, Ichimura S, Uzawa M.
    J Orthop Sci; 2002 Aug 31; 7(6):637-43. PubMed ID: 12486466
    [Abstract] [Full Text] [Related]

  • 27. Relationship between dental panoramic radiographic findings and biochemical markers of bone turnover.
    Taguchi A, Sanada M, Krall E, Nakamoto T, Ohtsuka M, Suei Y, Tanimoto K, Kodama I, Tsuda M, Ohama K.
    J Bone Miner Res; 2003 Sep 31; 18(9):1689-94. PubMed ID: 12968679
    [Abstract] [Full Text] [Related]

  • 28. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M.
    N Engl J Med; 1995 Nov 30; 333(22):1437-43. PubMed ID: 7477143
    [Abstract] [Full Text] [Related]

  • 29. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May 30; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 30. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 30; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 31. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
    Jiang Y, Li M, Xia W, Xing X, Yu W, Tian J, Meng X, Zhou X.
    Zhonghua Yi Xue Za Zhi; 2002 Sep 25; 82(18):1254-6. PubMed ID: 12425805
    [Abstract] [Full Text] [Related]

  • 32. The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: a randomized placebo-controlled study.
    Kung AW, Yeung SS, Chu LW.
    Calcif Tissue Int; 2000 Oct 25; 67(4):286-90. PubMed ID: 11000341
    [Abstract] [Full Text] [Related]

  • 33. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
    Iwamoto J, Takeda T, Ichimura S, Matsu K, Uzawa M.
    J Orthop Sci; 2003 Oct 25; 8(4):532-7. PubMed ID: 12898306
    [Abstract] [Full Text] [Related]

  • 34. Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis.
    Sanad Z, Ellakwa H, Desouky B.
    Climacteric; 2011 Jun 25; 14(3):369-77. PubMed ID: 21254911
    [Abstract] [Full Text] [Related]

  • 35. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL, Canadian Urology Research Consortium.
    Eur Urol; 2013 May 25; 63(5):927-35. PubMed ID: 23040208
    [Abstract] [Full Text] [Related]

  • 36. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.
    Ravn P, Clemmesen B, Christiansen C.
    Bone; 1999 Mar 25; 24(3):237-44. PubMed ID: 10071916
    [Abstract] [Full Text] [Related]

  • 37. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S.
    J Bone Miner Res; 2001 Jan 25; 16(1):113-9. PubMed ID: 11149474
    [Abstract] [Full Text] [Related]

  • 38. Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without renal dysfunction: a retrospective study.
    Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H.
    Drugs Aging; 2012 Feb 01; 29(2):133-42. PubMed ID: 22233456
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
    Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD.
    J Bone Miner Res; 1996 Mar 01; 11(3):337-49. PubMed ID: 8852944
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 48.